Floatz logo

Lentivirus Vector CCR5 shRNA

Recurrent Follicular Lymphoma

AIDS Malignancy ConsortiumPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

209 Active assets in the Recurrent Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Lentivirus Vector CCR5 shRNA is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
Burkitt lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →